Let me start the discussion by sharing my interests. I am deeply passionate about immunology and vaccine development, particularly in evaluating T-cell responses to vaccine nanoparticles. My focus is on understanding how these nanoparticles can stimulate the immune system, and I am eager to contribute to the development of in vitro screening assays to assess T cell proliferation. Through this work, I aim to help advance vaccine efficacy and contribute to the growing field of nanoparticle-based immunotherapies.
Our recent paper titled "Evaluating Nanoparticulate Vaccine Formulations for Effective Antigen Presentation and T-Cell Proliferation Using an In Vitro Overlay Assay," we explore the development and testing of nanoparticle-based vaccine formulations. Our focus is on evaluating how these formulations enhance antigen presentation and stimulate T-cell proliferation, which are essential for an effective immune response.
In our study, we focus on the crucial process of inducing T lymphocyte (T-cell) activation and proliferation with specificity against pathogens in vaccine formulation. Evaluating the ability of vaccine candidates to induce T-cell proliferation is vital for optimizing formulations for safety, immunogenicity, and efficacy. Our vaccine candidates use microparticles (MPs) and nanoparticles (NPs) to enhance antigen stability and target delivery to antigen-presenting cells (APCs), improving immunogenicity. To streamline vaccine candidate evaluation, we identified the need for a rapid, intermediate screening process to select promising candidates before advancing to costly and time-consuming in vivo tests. We demonstrate the effectiveness of an in vitro overlay assay system as a high-throughput preclinical method for evaluating early-stage vaccine formulations. By optimizing the carboxyfluorescein succinimidyl ester (CFSE) T-cell proliferation assay, we successfully tested various nanoparticulate vaccine formulations targeting pathogens like Neisseria gonorrhoeae, measles, H1N1 flu, canine coronavirus, and Zika. The assay revealed robust T-cell proliferation in response to vaccine treatment, with variations observed between bacterial and viral candidates and a dose-dependent immune response. Our findings highlight the potential of this assay to efficiently differentiate and quantify effective antigen presentation, offering valuable insights for the development and optimization of vaccine formulations.
What are your views on the potential of in vitro screening assays, like the overlay assay, to accelerate the vaccine development process?
------------------------------
Dedeepya Pasupuleti
Graduate Research Scientist
Mercer University
Atlanta GA
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------
Original Message:
Sent: 03-04-2025 12:57
From: Dedeepya Pasupuleti
Subject: Building Connections: Share Your Journey
Welcome to the PDPD community-one of the largest spaces to connect, share, and engage! We're excited to have you here. Introduce yourself and let us know what brings you to the community and what topics you're eager to explore.
Pharmaceutical Discovery and Preclinical Development is ever-evolving, and we want to hear what interests you most-whether it's AI in drug discovery, immuno-oncology, gene therapies, or preclinical safety models.
This space is for learning, sharing insights, and connecting with like-minded individuals. Your input will help shape future discussions and collaborations, so share what sparks your curiosity and the emerging trends you want to explore. Let's dive into the research shaping the future of pharmaceuticals together!
------------------------------
Dedeepya Pasupuleti
Graduate Research Scientist
Mercer University
Atlanta GA
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------